Ambys Medicines Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

Ambys Medicines is a biotechnology research company based in South San Francisco, California, focused on hepatocyte transplantation as a therapeutic approach for severe liver disease. It is developing a proprietary cell therapy platform, with its lead program AMI-918 and future engineered hepatocyte therapies intended to address a range of severe liver diseases, including those of acquired and genetic origins. The company has a small team, reported as 2-10 employees, and maintains information on its website. Ambys has expanded its leadership through multiple appointments in 2021–2022, including a Chief Strategy Officer, Chief Human Resources Officer, Vice President of Finance, and Vice President of Regulatory Affairs; it has also formed collaborations such as a partnership with the International Institute for the Advancement of Medicine in 2021. In 2018, Takeda Pharmaceuticals participated in a funding round supporting Ambys' development in cell therapies for liver disease.

Get verified Ambys Medicines emails free

Company overview Employee directory